stockportfolio.pro
Globus Medical, Inc. (GMED)
Healthcare · Medical Devices · NYSE
Globus Medical, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $563.99M | $635.98M | $712.97M | $785.37M | $789.04M | $958.10M | $1.02B | $1.57B | $2.52B | $2.94B |
| Gross profit | $429.29M | $485.52M | $553.56M | $605.39M | $571.58M | $718.88M | $759.12M | $1.02B | $1.48B | $1.98B |
| Net income | $104.34M | $107.35M | $156.47M | $155.21M | $102.28M | $149.19M | $190.17M | $122.87M | $102.98M | $537.87M |
| Net margin | 18.5% | 16.9% | 21.9% | 19.8% | 13.0% | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% |
Source: Globus Medical, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
What growth is priced into GMED stock?
At today's market cap of $11.00B, Globus Medical, Inc. is priced for free-cash-flow growth of about 6.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $588.77M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 34.2%/yr over the last five fiscal years and revenue 30.1%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 16 years of Globus Medical, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track GMED in your portfolio →
Globus Medical, Inc. financial history by metric
About Globus Medical, Inc.
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Globus Medical, Inc. — frequently asked questions
What is Globus Medical, Inc.'s revenue?
Globus Medical, Inc. (GMED) reported revenue of $2.94B for fiscal year 2025, up 16.7% from the prior year, according to its SEC filings.
Is Globus Medical, Inc. profitable?
Yes. GMED earned net income of $537.87M in fiscal 2025, a net margin of 18.3%.
What is GMED's P/E ratio?
Globus Medical, Inc. trades at a price-to-earnings ratio of about 18.9 based on the latest data in our nightly-refreshed cache.
How fast is Globus Medical, Inc. growing?
GMED's revenue grew at roughly 30.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Globus Medical, Inc. have?
As of fiscal year 2025, GMED carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Globus Medical, Inc.'s gross margin?
GMED's gross margin was 67.4% in fiscal 2025 — gross profit of $1.98B on revenue of $2.94B.
What is Globus Medical, Inc.'s market cap?
Globus Medical, Inc. (GMED) has a market capitalization of about $11.00B, based on the latest data in our nightly-refreshed cache.
When does Globus Medical, Inc.'s fiscal year end?
GMED's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into GMED stock?
At today's market cap of $11.00B, Globus Medical, Inc. is priced for free-cash-flow growth of about 6.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $588.77M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 34.2%/yr over the last five fiscal years and revenue 30.1%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Globus Medical, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.